What after Martine Rothblatt’s Insider Unload of United Therapeutics (UTHR) Stock?; Last Week ChemoCentryx, Inc. (CCXI) Coverage

April 11, 2018 - By Shannon Black

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. ChemoCentryx had 6 analyst reports since September 3, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of CCXI in report on Tuesday, August 8 with “Hold” rating. The firm has “Sell” rating given on Thursday, September 3 by Zacks. The stock has “Mkt Outperform” rating by JMP Securities on Tuesday, February 21. The firm earned “Sell” rating on Monday, September 21 by Zacks. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Thursday, August 10 by JMP Securities. On Tuesday, March 13 the stock rating was maintained by JP Morgan with “Overweight”. See ChemoCentryx, Inc. (NASDAQ:CCXI) latest ratings:

13/03/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $13 New Target: $16 Maintain

Analysts await United Therapeutics Corporation (NASDAQ:UTHR) to report earnings on April, 25. They expect $3.64 earnings per share, down 6.43% or $0.25 from last year’s $3.89 per share. UTHR’s profit will be $157.40M for 7.75 P/E if the $3.64 EPS becomes a reality. After $2.06 actual earnings per share reported by United Therapeutics Corporation for the previous quarter, Wall Street now forecasts 76.70% EPS growth.

Among 12 analysts covering United Therapeutics (NASDAQ:UTHR), 2 have Buy rating, 3 Sell and 7 Hold. Therefore 17% are positive. United Therapeutics has $244 highest and $95.0 lowest target. $144.50’s average target is 28.09% above currents $112.81 stock price. United Therapeutics had 32 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Credit Suisse on Thursday, February 22 with “Underperform”. The company was upgraded on Tuesday, April 3 by Credit Suisse. The firm earned “Hold” rating on Thursday, October 26 by Cowen & Co. As per Friday, July 31, the company rating was maintained by Argus Research. Cowen & Co maintained the shares of UTHR in report on Thursday, July 27 with “Hold” rating. As per Monday, November 13, the company rating was maintained by Wedbush. As per Thursday, September 14, the company rating was maintained by Jefferies. The firm has “Sector Perform” rating given on Wednesday, July 29 by RBC Capital Markets. Ladenburg Thalmann downgraded United Therapeutics Corporation (NASDAQ:UTHR) on Thursday, February 23 to “Neutral” rating. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Hold” rating by H.C. Wainwright on Thursday, October 26.

Since October 12, 2017, it had 0 insider purchases, and 11 sales for $24.70 million activity. ROTHBLATT MARTINE A also sold $4.93 million worth of United Therapeutics Corporation (NASDAQ:UTHR) shares.

21,513 shares of United Therapeutics Corp were sold by Martine Rothblatt, the company’s Chairman & CEO. These insider shares are valued at around $2,385,368 which has been calculated on the basis of the average transactions stock price ($110.9 for share). It seems she is very active lately as in the last 30 days, she quietly unloaded additional 217,569 shares of the company, worth $24,400,607 USD. Due to the size of the trade there is little chance that it will go a secret. Martine Rothblatt currently has in hand 683,795 shares or 1.58% of United Therapeutics Corp’s market cap.

The stock increased 0.75% or $0.84 during the last trading session, reaching $112.81. About 162,705 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has declined 23.69% since April 11, 2017 and is downtrending. It has underperformed by 35.24% the S&P500.

Investors sentiment increased to 1.14 in Q4 2017. Its up 0.15, from 0.99 in 2017Q3. It is positive, as 26 investors sold United Therapeutics Corporation shares while 112 reduced holdings. 53 funds opened positions while 105 raised stakes. 40.90 million shares or 1.42% less from 41.49 million shares in 2017Q3 were reported. Delta Asset Mngmt Ltd Llc Tn, a Tennessee-based fund reported 50 shares. Amalgamated Bankshares owns 8,685 shares for 0.03% of their portfolio. Synovus holds 5,615 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt holds 0.01% in United Therapeutics Corporation (NASDAQ:UTHR) or 6,312 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Mgmt Corp invested in 6,100 shares or 0.01% of the stock. Alphamark Advsr Limited Liability Company has invested 0% in United Therapeutics Corporation (NASDAQ:UTHR). Moreover, Eqis Capital Mngmt has 0.02% invested in United Therapeutics Corporation (NASDAQ:UTHR) for 2,875 shares. Texas Permanent School Fund stated it has 29,210 shares or 0.05% of all its holdings. British Columbia Management owns 0.01% invested in United Therapeutics Corporation (NASDAQ:UTHR) for 5,967 shares. Bluecrest Capital Mngmt Limited accumulated 3,084 shares. Prudential Financial has 234,892 shares. Bokf Na invested in 0.08% or 20,414 shares. Etrade Cap Management Limited Liability Corp has invested 0.01% in United Therapeutics Corporation (NASDAQ:UTHR). Tiaa Cref Inv Ltd Liability Corporation holds 0.01% or 139,381 shares. 40,072 were accumulated by Dock Street Asset Mngmt.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company has market cap of $4.88 billion. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It has a 12.12 P/E ratio. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $593.41 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 33.69 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

The stock decreased 1.78% or $0.22 during the last trading session, reaching $12.13. About 129,975 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 81.17% since April 11, 2017 and is uptrending. It has outperformed by 69.62% the S&P500.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart